Outpatient CAR-T Therapy May Offer Cost Savings, but More Data Are Needed
Administering CAR-T cell therapy in the outpatient community setting is estimated to save more than $30,000 per patient.
Lymphoma
LYMPHOMA ADVISOR
FEATURED CONTENT
-
-
What Factors Influence Hematological Recovery in Patients Who Receive CAR-T Therapies?
Two studies characterize hematological recovery after CAR-T cell therapy. -
High Response Rates to CAR-T Seen in Mantle Cell Lymphoma
In the phase 2 ZUMA-2 study, KTE-X19 CAR-T therapy showed a lasting clinical benefit and manageable side effects in relapsed/refractory mantle cell lymphoma. -
COVID-19 Pandemic Delaying Treatments of Hematologic Cancers
Some US medical centers have canceled treatments and all centers have altered their policies and procedures out of precaution related to the COVID-19 pandemic. -
BEGEV Salvage Regimen Linked to High Complete Remission Rates
5-year results from that a study on BEGV have confirmed its benefits in classical Hodgkin lymphoma.
VIDEO SERIES
LYMPHOMA NEWS
Patient Relapse Time After Auto-HCT in Chemosensitive DLBCL Does Not Appear to Influence PFS
Dual-Targeting CAR-T Appears Active in R/R DLBCL
Allogeneic CAR-T Therapies Appear Safe in LBCL/FL
Emapalumab Effective for Pediatric Primary Hemophagocytic Lymphohistiocytosis
Study Links DLBCL and CLL Incidence to Race and Ethnicity, Urban Status
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
